Interimarketing
  • Home
  • About
  • Work
  • Services
  • Blog
  • Contact
  • Home
  • About
  • Work
  • Services
  • Blog
  • Contact

The Storytelling Lab

Storytelling | Strategy | Implementation

Save the Cat! For Scientists

12/3/2025

 
​A Hollywood Approach to Better Scientific Storytelling
by Meghan O'Sullivan
Picture
Save the Cat is a storytelling framework originally created for screenwriters by Blake Snyder. It breaks stories into simple, repeatable beats that clarify what an audience needs at every stage—from the opening image to the final payoff. I recently stumbled upon it through a recommendation (yes, I’m writing a novel), and novelists love it for the structure and emotional logic it provides.

What surprised me most was this: the same principles that help shape a novel are exactly the ones scientists, healthcare teams, and biotech innovators are missing when they communicate their work.

So I pulled out the most relevant beats and merged them with what I know about scientific messaging and commercialization.

The result is a fresh way to craft stories that actually move your audience.

1. Your Product or Service Is Not the Hero of the Story

​Save the Cat teaches writers to build stories around a hero the audience cares about. In scientific storytelling, that hero is your buyer — not your product​. Your hero is the person your innovation is meant to help, not the platform, not the algorithm, not the instrument.
​
Meet your hero: Dr. Elena Ramirez, Director of Translational Research at a global pharma company.

At 6:45 a.m., Elena badges into the lab, coffee still too hot to drink, already bracing for whatever the night shift left behind. The automation queue stalled again. Extracted samples timed out. Bioinformatics flagged a run for low-quality metrics. Clinical trial deadlines are creeping closer, and leadership wants data—fast. She sets down her bag, scans the report, and whispers, “Not this again.”​
Picture
This is your hero.

Picture
In the weekly meeting, the automation engineer pushes for cleaner sample prep, the bioinformatician argues for consistent data capture, the bench scientist wants fewer workarounds, and the project manager pleads for predictable timelines. Leadership, meanwhile, is demanding speed and reproducibility at the same time. Elena looks around the table and thinks, "We’re rowing in five different directions."

That’s your narrative spine. Not “efficiency.” Not “speed.” Not “workflow optimization.”
Those are outcomes, not stories.​
2: Every story has a "central problem" even if your product solves several.

The story can set out to solve multiple problems as long as they anchor to a single narrative spine. But here’s the issue: the narrative spine in most life science marketing is often too broad to make your audience care.

Common Narrative Spine: Improve workflow efficiency (so what?)
Symptoms: manual bottlenecks | data fragmentation | slow turnaround times | mitigate risk (all white noise)

What to do Instead?

​Lead with narratives that demonstrate real tensions and problems that are human:
​
  • Our team isn't on the same page
  • Everyone’s exhausted by tedious workarounds.
  • One unexpected thing can break EVERYTHING!
  • Nobody fully trusts the workflow.

​See the difference? 

3. Reveal the “All Is Lost ” moment -- where persuasion happens.

Every compelling story has a breaking point, the moment when the hero realizes the old way no longer works. I call these "war stories" in my marketing workshops. They can be slides, a one pager, or simple story told by a rep.

​Here's how you use them:
​
  • Show the moment the old way fails your buyer.
  • Make the consequences real (missed deadlines, failed runs, burnout).
  • Use a character to mirror your audience so they see themselves.
  • Let the pain land before introducing your solution.
  • Position your product as the turning point, not the hero.​
Picture
At 8:12 a.m. that Tuesday, Elena’s Slack lights up with a string of alerts. The entire sequencing run failed—low yield, unusable data, and several critical clinical trial samples now at risk. Deadlines collapse instantly. When her team gathers around the conference table, the fatigue is palpable. Elena finally exhales and says what everyone is thinking: “We can’t keep doing it this way.”

Your audience leans in here, not because of your features, but because they recognize the pain.

4. The Solvable Moment (the missing beat most scientific stories skip)

After the breaking point comes the shift, the moment when the hero sees a path forward. In story structure, this is the beat where a new character enters, the one who makes the problem solvable. In this case, that character is either you or your internal champion. They help the hero see the problem differently, and that creates the revelation.

How to create this moment in your marketing:
  • Show the part of the problem your buyer hasn’t been able to see. Reveal a pattern.
  • Reveal it with one clear moment or visual.
  • Introduce your product only when it makes the fix obvious.
  • Let the buyer think, “Oh, that’s what’s been going wrong.”​

Sales teams must equip internal champions with these tools. Sometimes that comes in the form of a diagnostic, like a savings calculator, workflow audit, or demo—that helps the buyer see the problem clearly.

​

Picture
Later that afternoon, Elena is reviewing the failed run with her team when the lab systems engineer steps in and opens the new system they’ve been evaluating. She clicks through a simple workflow view, and the room goes quiet. On the screen, the bottleneck they’ve been debating all day is suddenly obvious. Elena studies the image and says, “This is fixable."

Picture
But Elena’s payoff is a moment worth imagining:

​A month later, Elena walks into something she barely recognizes: calm. The queue is clean, metadata is captured automatically, and analysis has already begun. No frantic messages, no missing files, no scrambling to catch up. For the first time all year, the biomarker program is actually on schedule. During the morning huddle, her team laughs. And at 5:00 p.m., they leave on time, energized instead of drained. Elena lingers in the doorway, taking in the calm, predictable flow of a process finally working​.

That’s a payoff your audience can feel. And once they can feel it, they can believe it. Feeling is believing. 
5. The payoff must be vivid.

Novelists call it the “Final Image”—the picture of life after transformation. Most scientific storytelling collapses here. Companies list benefits instead of painting a scene.

​How to use this in your marketing:
​
  • Show what life looks like after the transformation, not just the features and benefits.
  • Make the benefits tangible: calmer mornings, cleaner data, fewer delays.
  • Use a moment your buyer can visualize happening in their own lab. Not the whole workflow — just one relatable moment.​

Sample Payoff Narratives

  • ​The run that didn’t need troubleshooting
  • The QC report generated in minutes
  • The batch that didn’t stall mid-process
  • ​The batch that didn't get contaminated
  • The sample that didn’t get lost in handoff

​These scenes sell because they’re lived experiences, not claims. And scenes like these are powerful because they’re instantly recognize. 





​



Picture
Contact Meghan
Meghan O’Sullivan is a marketing strategist and storyteller specializing in life sciences, healthcare and technology. She helps sales and marketing teams turn complex science into clear, compelling narratives that motivate buyers and build brand loyalty.
​
Conclusion: A good story gives your buyer a reason to care and the courage to change

When you shift from industry language to true storytelling, something changes: buyers finally see themselves in the story. They don’t just understand your innovation, they feel why it matters. That’s the moment your message stops sounding like a pitch and starts becoming the solution they’ve been waiting for. 

Every story needs a final image.
This is yours.


Picture yourself telling a story your audience instantly recognizes, one where they nod along because they feel exactly what you are describing. No more feature listing. No more efficiency buzzwords. Just a narrative so clear and grounded that your buyer can imagine what their world would finally feel like when the struggle ends and their new life begins.

AI Is No Longer A Differentiator in the Life Sciences — Here’s What Is

2/24/2025

 
Picture

The AI Echo Chamber in Life Sciences

AI has become the default talking point in biotech, life sciences, and pharma marketing. Nearly every company claims to have AI-driven platforms, AI-powered insights, or AI-enhanced workflows.The problem? Everyone is saying the same thing, but not everyone is doing the same thing.

A few years ago, adding AI to a pitch might have been enough to grab attention. Today, it is simply assumed. Life sciences companies using AI for drug discovery, diagnostics, clinical trials, and automation are now becoming the norm. And simply stating that your company uses AI does not differentiate you. Investors, customers, and partners expect AI to be part of modern life sciences solutions. 

The real question is: How is your AI delivering measurable impact?

AI Is Now a Presumed Attribute In Most Circles

If your messaging focuses on “We use AI to improve efficiency” or “Our AI-powered platform accelerates research”, you are blending into the noise rather than standing out. Instead of making AI the focus, the key is to shift the conversation to outcomes, differentiation, and execution.

The Wrong Way: Our AI-powered platform accelerates drug discovery.
The Right Way: Our platform reduced target identification time by 60% by training deep learning models on 20 years of experimental data.
Takeaway: AI is not the story—the impact of AI is.

Lead with the Problem, Not the Technology

Life sciences professionals and investors care more about the problem being solved than the technology behind it. AI is only valuable if it delivers a tangible benefit. No one is buying AI itself—they are buying better, faster, more efficient solutions.

The Wrong Way: We use AI and machine learning to optimize clinical trials.
The Right Way: Our platform reduces patient recruitment time by 40%, helping clinical trials reach completion faster.
Takeaway: If your AI pitch does not clearly address a real industry challenge, it is just another buzzword.

What Actually Differentiates Your AI?
​

If AI itself is not a differentiator, what is? Companies that stand out focus on:
  • Data Quality & Exclusivity – Does your AI model train on proprietary, high-quality data?
  • Algorithmic Superiority – Is your approach to AI meaningfully different from competitors'?
  • Workflow Integration – Does your AI seamlessly fit into existing lab, research, or clinical workflows?
  • Proven Results – Have you demonstrated real-world impact with measurable improvements?

The Wrong Way: Our AI-driven platform improves biomarker discovery.
The Right Way: Our AI model, trained on 500,000 patient samples, predicts disease biomarkers with 92% accuracy—30% higher than traditional methods.
Takeaway: AI is expected—what makes your approach unique is what matters.

Avoid the One-Size-Fits-All AI Pitch

The effectiveness of an AI-driven life sciences solution depends on who is hearing the message. A pitch for a biotech VC will not resonate the same way with a pharma executive, a hospital administrator, or a regulatory body.
  • Investors want to see market potential, scalability, and financial returns.
  • Scientists and R&D teams care about accuracy, validation, and experimental reproducibility.
  • Executives are focused on efficiency, cost reduction, and integration into existing workflows.


The Wrong Way: A generic AI claim presented to all stakeholders.
The Right Way: Tailoring the message to highlight what matters most to each audience.
Takeaway: AI messaging must be aligned with the priorities of the person receiving it.

AI Is Not the Future—Execution Is
​

The companies that will succeed in AI-driven life sciences are those that deliver results, not just promises.To differentiate in an AI-saturated market:
  • Showcase real-world case studies. Demonstrate how AI is already making a measurable impact.
  • Clarify your competitive edge. What makes your AI different from other solutions?
  • Ensure seamless adoption. AI must integrate into existing workflows without adding complexity.
Takeaway: Investors and customers are no longer impressed by AI alone. They want execution, proof, and real-world results.

Final Thoughts: Make the Story About Outcomes, Not AI.

Whitepapers, Cold Emails, and Long Sales Calls? Today's B2B Buyers Say No Thanks.

2/21/2025

 
Picture
The Next Generation of B2B Buyers is Changing the Game

For decades, B2B marketing followed a familiar formula: whitepapers, cold outreach, lead capture forms, and long sales cycles driven by reps. But the next generation of B2B buyers doesn’t want to be sold that way. According to Forrester, younger decision-makers—millennials and Gen Z—are taking the lead in high-stakes B2B purchases, representing 71% of B2B buyers. And they’re bringing their digital-first, self-service expectations with them. If your marketing strategy still assumes buyers want long PDFs, cold emails, and scheduled calls with sales reps, it’s time for a refresh.

B2B Buyers Do Their Own Research—Make Sure They Find You

The days of sales teams owning the buyer journey are over. Today’s buyers are more independent, with 72% preferring a rep-free experience when making a purchase decision. (No offense to my sales friends—you’re still essential, but your strength is in closing, not guiding the entire journey.)

Instead of waiting for outreach, they:

✔ Find answers through Google, industry forums, and peer networks
✔ Look for social proof—customer reviews, testimonials, and third-party validation
✔ Expect on-demand access to information—not endless lead capture forms

What This Means for Marketers:
  • Stop gating everything—buyers are more likely to engage if they don’t have to trade their email for basic content. 
  • Invest in SEO, thought leadership, and digital content that helps them make decisions on their own.
  • Build trust with case studies, customer stories, and transparent product details.

Buyers Expect a B2C-Like Experience—Fast, Personalized, and Seamless

Younger B2B buyers have grown up in a frictionless, on-demand world—and they expect the same from their professional purchasing experiences.
  • They want instant answers, not delayed responses from a sales team.
  • They expect pricing transparency, not hidden costs and discovery calls.
  • They prefer asynchronous communication, like chat, Slack, and LinkedIn messages over long email threads.

What This Means for Marketers:
  • Optimize your website for fast, easy access to information—no one wants to dig through PDFs.
  • Offer interactive tools, demos, and trials so buyers can experience the value before committing.
  • Rethink your contact strategy—some buyers will want a rep, but many will prefer to self-serve.

Thought Leadership and Community Matter More Than Ever

Today’s buyers don’t just want product specs—they want insights, expertise, and connections.
  • Social selling is on the rise. Buyers engage with brands they see adding value on LinkedIn, in Slack groups, and through live events.
  • Trust beats promotion. A well-placed case study, peer recommendation, or research-backed insight is more persuasive than a generic pitch.
  • B2B communities are replacing cold outreach. Many buyers rely on referrals, peer discussions, and industry groups before even considering a vendor.

What This Means for Marketers:
  • Position your company as a trusted resource in your space—be part of the conversations buyers are already having.
  • Invest in content that educates, not just sells. Webinars, research reports, and expert insights build credibility.
  • Encourage community engagement. Support industry groups, publish guest content, and interact authentically on social platforms.

If Your Sales Cycle Feels Slow, Your Buyers Are Already Moving On

B2B buying used to mean weeks of research, long sales cycles, and multiple touchpoints before a deal closed. But younger buyers don’t have time for that.They are less brand-loyal, more open to new vendors, and move faster than previous generations. If your buying process is slow or outdated, they’ll find an alternative.

What This Means for Marketers:
  • Streamline your purchase process--make it easier to evaluate, demo, and buy.
  • Use AI and automation to personalize outreach and respond quickly.
  • Measure drop-off points in your funnel—where are buyers getting frustrated and walking away?

Final Thoughts:
B2B Marketing Needs to Catch Up.

The next generation of B2B buyers expects instant access, self-service options, and valuable insights upfront. They aren’t responding to cold emails, downloading PDFs, or waiting for sales calls. If your marketing strategy hasn’t evolved to meet them where they are, you’re already behind. Unlike previous generations who may have responded more to traditional corporate messaging, younger B2B buyers expect marketing that feels human, narrative-driven, and aligned with their values.

​So ask yourself: Are you making it easier for buyers to engage—or harder? 

Top 5 Mistakes Life Science Companies Make When Communicating to Investors

2/19/2025

 
Picture

Messaging Missteps That Can Cost You Funding

Securing investment in life sciences isn’t just about having groundbreaking science — it’s about telling the right story to the right audience. But what you need to understand is that one size story does not fit all. While some investors specialize in biotech and diagnostics—often with PhDs on their team or at the helm—others have limited scientific expertise and instead focus on financial projections, market potential, and a compelling narrative.

The challenge? Too many life science companies misfire when communicating their value, leaving investors confused, skeptical, or uninterested. Why? Because they don’t understand their audience.

Mistake #1: Leading with Science Instead of the Problem

Too many pitches start with technology rather than why it matters!

The Wrong Way: 
We developed a novel CRISPR-based molecular diagnostic platform that integrates AI for enhanced specificity.

The Right Way: 
Current diagnostic tests miss 30% of cases. Our AI-powered CRISPR technology reduces false negatives, improving early detection and saving lives.

How we fixed it: Investors care about the impact first—hook them with the problem, then explain your solution. 

Mistake #2: Overloading with Jargon & Data

Not every investor has a PhD. But even those who do, do not want to decode a wall of scientific text. 

The Wrong Way:  Our platform leverages next-gen sequencing with an adaptive hybridization capture system, achieving a 99.97% concordance rate.

The Right Way: Our test is faster and more accurate than traditional sequencing, making early disease detection easier and more affordable.

How We Fixed It:  Keep technical details concise and explain them in layman’s terms.


 
Mistake #3: Overpromising or Ignoring Risks
 
The Wrong Way: Our AI-driven drug discovery platform guarantees breakthrough cures for rare diseases.

The Right Way: Our AI-driven platform accelerates drug discovery for rare diseases by identifying promising candidates faster, with early data suggesting a higher success rate in preclinical models.

How We Fixed It: Avoid absolute claims—investors value measurable progress and realistic expectations over exaggerated guarantees. Highlight the potential impact while acknowledging development stages.

 
Mistake #4: Ignoring the Competitive Landscape

Experienced investors can spot gaps in your market analysis a mile away—make sure your assessment is realistic, well-researched, and defensible.

The Wrong Way: We really have no direct competitors. Nobody is doing what we’re doing.

The Right Way: While no one offers our exact approach, companies X and Y provide similar solutions. Here’s why we are different.

How We Fixed It: Investors expect competition—even if it’s with the status quo. Show that you understand the market, know your differentiators, and can compete effectively.


Mistake #5  Focusing Too Much on Science Not Strategy

Great science doesn’t guarantee commercial success. Most of you know this, but this is a good check list to follow. Does your story include the following details?
  • How big is the market?
  • Are your projections realistic?
  • What’s the revenue model or end game?
  • Who are the competitors? How are you different?
  • What’s the regulatory pathway?
  • How will you scale?
  • How long will it take to bring your product to market?
  • How you plan to communicate traction and milestones​​

Ready to make your story investor ready?  Let’s talk. 
Contact Us

Features Are Meaningless Until Your Audience Cares About the Problem

2/11/2025

 
tech person saying why care?
Life science companies often flood their audiences with an avalanche of scientific and technical details the moment they land on a website. The instinct is understandable—you’ve achieved a breakthrough, and you want to share it with others. You assume your audience will immediately grasp what you’ve done and how it benefits them.

But here’s the reality: People are busy! They don’t have time to “figure it out.”

And yes, I’ve heard this rebuttal more than once: “Well, if they don’t immediately understand what we’ve done here, then they really aren’t our target market.”

Really? Let’s examine this a bit further.

Not everyone thinks like an innovator

Only 2.5% of your market consists of innovators—those who actively seek out new, cutting-edge solutions. They’ll dig through your website, click through multiple pages, and hunt for the “what’s in it for me.” And if you land a few of these clients early on, you might think, “Great! People get it! We’re on a roll!”

Not so fast.

The next group--the 12.5% who are early adopters—think differently. They don’t have time to connect the dots from your innovation to their problems. In many cases, they don’t even realize they have a problem. That means your job isn’t just to explain the solution—you have to educate them on why they should care in the first place.

The majority needs a different story

Once you move past early adopters, you’ll encounter the early and late majority—a much larger, more skeptical group. They don’t obsess over features. They’re not interested in the technical specs of your innovation. Instead, they ask:

  • Who else is using this?
  • What results have they seen?
  • Am I missing out on something important?
​
Tips for Creating a Story for Every Type of Buyer

  1. Start with the person, not the product. Who is experiencing the challenge, and what’s at stake for them?
  2. Create multiple variations of your story. Your audience isn’t all at the same stage in their decision-making process, so your story should evolve to meet them where they are. This means you need to have different messages peppered throughout your website for each buyer type as we describe above.
  3. Introduce the struggle. What obstacles do they face before they even realize a solution exists?
  4. Present the solution as part of their transformation. Show how their world changes—not just what your technology does.
  5. End with the resolution. What impact does this have on their daily work, efficiency, or outcomes?

The bottom line
​

No two buyers are alike. You need multiple stories and multiple journeys — not just a flood of features and tech talk. People don’t buy features. They buy a better version of their world. This means your story can't just inform — it needs to be compelling enough to make your audience care.



​Need help telling your story? Contact us!

Submit
<<Previous

    Authors

    Meghan O'Sullivan
    Cheryl Allen
    Gabe d'Annunzio

    Archives

    December 2025
    February 2025
    February 2024
    January 2024
    July 2023
    June 2023
    May 2023
    March 2023
    November 2022
    September 2022
    April 2022
    March 2022
    February 2022
    March 2021
    January 2017

    Categories

    All

    RSS Feed

Interimarketing™ is a DBA of O'Sullivan Communications, Inc. (Copyright 2025)
Massachusetts-Based - Available for Remote Work Throughout North America
Privacy Policy
​Terms of Use